Subgroup analysis of ΔSOFAday07 after PSM
| Tα1 (n = 111) | Placebo (n = 111) | P value | |||
|---|---|---|---|---|---|
| n | Median, IQR | n | Median, IQR | ||
| Age | |||||
| Non-elderly | 37 | 40 (22, 72) | 39 | 22 (–8, 61) | 0.062 |
| Elderly | 74 | 47 (17, 67) | 72 | 35 (1, 57) | 0.066 |
| Sex | |||||
| Male | 84 | 43 (16, 66) | 87 | 33 (–2, 58) | 0.056 |
| Female | 27 | 54 (29, 75) | 24 | 31 (–8, 66) | 0.117 |
| Initial mHLA-DR | |||||
| Immunoparalysis | 26 | 47 (13, 73) | 29 | 31 (–1, 60) | 0.116 |
| No immunoparalysis | 85 | 45 (21, 67) | 82 | 33 (–6, 60) | 0.047 |
| Lymphocyte day 0 | |||||
| < 0.7 × 109/L | 38 | 56 (30, 78) | 39 | 44 (3, 62) | 0.102 |
| 0.7–1.1 × 109/L | 33 | 44 (16, 62) | 31 | 27 (–1, 59) | 0.225 |
| > 1.1 × 109/L | 39 | 39 (15, 67) | 41 | 26 (–12, 59) | 0.093 |
| Pre-existing conditions | |||||
| No | 18 | 55 (36, 71) | 21 | 0 (–19, 51) | 0.006 |
| Yes | 93 | 42 (18, 68) | 90 | 38 (7, 61) | 0.207 |
| Initial SOFA score | |||||
| ≤ 8 | 70 | 43 (18, 70) | 73 | 30 (–11, 60) | 0.033 |
| > 8 | 41 | 45 (26, 67) | 38 | 35 (17, 60) | 0.198 |
| APACHE II score | |||||
| ≤ 21 | 55 | 48 (19, 76) | 61 | 32 (–10, 60) | 0.048 |
| > 21 | 56 | 43 (20, 62) | 50 | 33 (4, 57) | 0.124 |
| Intervention time | |||||
| Early | 41 | 58 (32, 78) | 48 | 39 (15, 62) | 0.041 |
| Delayed | 70 | 36 (16, 63) | 63 | 27 (–16, 56) | 0.055 |